Emerging Therapies For The Treatment Of Patients With Vestibular Schwannomas
Publication Date: February 1, 2018
Last Updated: March 14, 2022
Recommendations
MEDICAL THERAPY
It is recommended that bevacizumab be administered in order to radiographically reduce the size or prolong tumor stability in patients with neurofibromatosis type 2 (NF2) without surgical options. (Level III)
318512
It is recommended that bevacizumab be administered to improve hearing or prolong time to hearing loss in patients with NF2 without surgical options. (Level III)
318512
Lapatinib may be considered for use in reducing vestibular schwannoma size and improvement in hearing in NF2. (Level III)
318512
Erlotinib is not recommended for use in reducing vestibular schwannoma size or improvement in hearing in patients with NF2. (Level III)
318512
Everolimus is not recommended for use in reducing vestibular schwannoma size or improvement in hearing in NF2. (Level III)
318512
It is recommended that aspirin administration may be considered for use in patients undergoing observation of their vestibular schwannomas. (Level III)
318512
Perioperative treatmentwith nimodipine (or with the addition of hydroxyethyl starch) should be considered to improve postoperative facial nerve outcomes and may improve hearing outcomes. (Level III)
318512
Title
Emerging Therapies For The Treatment Of Patients With Vestibular Schwannomas
Authoring Organization
Congress of Neurological Surgeons